SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1208)
Related Products (1208)
-
Recombinant Proteins (196)
-
Lamivudine triphosphate
0 ImagesCat. No.: HY-131603CAS No.: 143188-53-8Synonyms: 3TCTPLamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.
-
Antimicrobial agent-12
0 ImagesCat. No.: HY-151502Antimicrobial agent-12 is a potent antibacterial agent with SARS-CoV-2 inhibitory activity.
-
SARS-CoV-2 Mpro-IN-5
0 ImagesCat. No.: HY-151901CAS No.: 3023276-79-8SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 14.7 nM.
-
αGalCer-RBD
0 ImagesCat. No.: HY-144120αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain
-
Andrographolide-d
0 ImagesCat. No.: HY-N0191SSynonyms: Andrographis-dAndrographolide-d (Andrographis-d) is the deuterium labeled Andrographolide (HY-N0191). Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
-
PLpro-IN-8
0 ImagesCat. No.: HY-168259PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM.
-
MI-30
0 ImagesCat. No.: HY-180318CAS No.: 2698348-97-7
-
Mpro ligand 2
0 ImagesCat. No.: HY-161791CAS No.: 2816967-14-1
-
SARS-CoV-2-IN-21
0 ImagesCat. No.: HY-147516CAS No.: 89971-88-0SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research.
-
Indinavir sulfate ethanolate
0 ImagesCat. No.: HY-B0689BCAS No.: 2563866-80-6Synonyms: MK-639 ethanolate; L735524 ethanolateIndinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibitor.
-
SARS-CoV-2 Mpro-IN-4
0 ImagesCat. No.: HY-151900SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM.
-
Azelastine-13C,d3 hydrochloride
0 ImagesCat. No.: HY-B0462SAzelastine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Azelastine hydrochloride. Azelastine-13C,d3 (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine-13C,d3 (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
-
SARS-CoV-2 Mpro-IN-6
0 ImagesCat. No.: HY-152108CAS No.: 2768834-48-4SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 Mpro inhibitor with an IC50 of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3.
-
Hydroxychloroquine Impurity E
0 ImagesSynonyms: 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanolHydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
-
VPC285785
0 ImagesCat. No.: HY-181983CAS No.: 2759276-10-1VPC285785 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 0.8 μM and a Kd of 2.7 μM. VPC285785 functionally inhibits the viral main protease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections.
-
SARS-CoV MPro-IN-2
0 ImagesCat. No.: HY-N144101CAS No.: 81418-42-0SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
-
SARS-CoV-2-IN-18
0 ImagesCat. No.: HY-143470CAS No.: 184904-82-3SARS-CoV-2-IN-18 (Compound 26) is a potent SARS-CoV-2 3C-like protease inhibitor with an IC50 of 45 nM.
